Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05538897

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

Sponsor: NRG Oncology

Conditions FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma Metastatic Endometrial Endometrioid Adenocarcinoma Recurrent Endometrial Endometrioid Adenocarcinoma

Interventions Biospecimen Collection Computed Tomography Ipatasertib Magnetic Resonance Imaging Megestrol Acetate

Updated 38 times since 2022 Last updated: Mar 12, 2026 Started: Mar 31, 2023 Primary completion: Jan 31, 2027 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma and is currently ongoing. NRG Oncology leads this study, which shows 38 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

38 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

▶ Show 33 earlier versions

Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Suspended → Recruiting
Jan 2024 — Mar 2024 [monthly]

Suspended PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Sep 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Anaconda, United States , Ankeny, United States , Ann Arbor, United States , Augusta, United States , Aurora, United States , Battle Creek, United States , Beachwood, United States , Bethesda, United States and 108 more locations